Michael Andrew Chambers - 16 Aug 2024 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Director
Signature
/s/ Ryan Brown as Attorney-in-Fact for Michael Chambers
Issuer symbol
SRPT
Transactions as of
16 Aug 2024
Transactions value $
$4,955,728
Form type
4
Filing time
20 Aug 2024, 08:00:04 UTC
Previous filing
05 Mar 2024
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Purchase $1.74M +13.1K +5.31% $133.07 260K 16 Aug 2024 By Revocable Trust F1
transaction SRPT Common Stock Purchase $2.45M +18.3K +7.03% $134.06 278K 16 Aug 2024 By Revocable Trust F2
transaction SRPT Common Stock Purchase $761K +5.65K +2.03% $134.66 284K 16 Aug 2024 By Revocable Trust F3
holding SRPT Common Stock 8.28K 16 Aug 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $132.46 to $133.46, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.47 to $134.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $134.48 to $134.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.